The National Institute of Allergies and Infectious Diseases is leading COVID-19 clinical trial efforts through a large-scale network, called the COVID-19 Prevention Network (CoVPN). Dr. Jim Kublin, the executive director of operations program for CoVPN, shares more about this government-funded clinical trials network for COVID-19, the importance of diversity in research, and how tech is rapidly advancing medical discoveries.
HealthCast
Season 2
Episode 1
23m listen
Ensuring Participant Diversity in COVID-19 Vaccine Trials
Share
Modern technology has the power to overcome clinical trial participation challenges.
-
Dr. Jim Kublin Executive Director of Operation Programs CoVPN
Related Content
-
IHS is Positioning Cybersecurity as Patient Safety
IHS CISO Benjamin Koshy explains why cybersecurity is critical to patient safety and how the agency secures care delivery in remote areas.
7m watch -
DLA CIO: Securing AI Pipelines Is Now a Core Mission
With small vendors comprising most of its supplier base, Roberts says stronger oversight and zero-trust controls are critical to counter cyber threats.
6m watch -
How to Thrive in Cybersecurity Without Burning Out
Explore mental health in cybersecurity including imposter syndrome, burnout, boundaries and building a sustainable career in high-pressure tech environments.
34m watch -
Project ARIA Pushes AI From Concept to Soldier-Ready Capability
Army CTO Gabe Chiulli explains how Project ARIA is accelerating AI adoption, cutting red tape and delivering tools to soldiers at speed.
20m watch
